🔴 Viking Therapeutics is trading 4.13% down today as hotter-than-expected inflation revives rate concerns

Viking Therapeutics is trading at $25.55, down 4.13%, during the October 14 session as hotter-than-expected September inflation revived interest-rate concerns.

• The Nasdaq was down 2.03%, while the S&P 500 fell 1.36%.
• On October 14, Viking announced the start of two Phase 3 trials for oral VK2735; reporting does not establish the announcement as the reason for the decline.
• The move is more consistent with broad risk-off pressure than a clear company-specific negative catalyst.